Any feedback?
Please rate this page
(search_result.php)
(0/150)

BRENDA support

Refine search

Search Natural Substrates/ Products (Substrates)

show results
Don't show organism specific information (fast!)
Search organism in taxonomic tree (slow, choose "exact" as search mode, e.g. "mammalia" for rat,human,monkey,...)
(Not possible to combine with the first option)
Refine your search
Search for synonyms (with exact matching search term)

Search term:

Results 1 - 8 of 8
EC Number Natural Substrates Commentary (Nat. Sub.)
Display the word mapDisplay the reaction diagram Show all sequences 3.10.1.1heparan sulfate + H2O -
Display the word mapDisplay the reaction diagram Show all sequences 3.10.1.1heparan sulfate + H2O degradation of heparan sulfate
Display the word mapDisplay the reaction diagram Show all sequences 3.10.1.1heparin + H2O -
Display the word mapDisplay the reaction diagram Show all sequences 3.10.1.1heparin + H2O degradation products of
Display the word mapDisplay the reaction diagram Show all sequences 3.10.1.1more congenital deficiency of sulfamidase leads to mucopolysaccharidosis type IIIA or Sanfilippo syndrome, a lysosomal storage disorder, with consequent accumulation of partially degraded heparan sulfate in lysosomes and the central nervous system as the predominant site of tissue damage, overview
Display the word mapDisplay the reaction diagram Show all sequences 3.10.1.1more enzyme defiency leads to defective lysosomal degradation of the glycosaminoglycan heparan sulfate, mutations of the enzyme are responsible for mucopolysaccharidosis type IIIA, i.e. Sanfilippo A syndrome, onset and progression of the disease, overview
Display the word mapDisplay the reaction diagram Show all sequences 3.10.1.1more reduced activity of sulfamidase results in intracellular accumulation of heparan sulfate, with the brain the primary site of pathology, e.g. in mucopolysaccharidosis type IIIA, or Sanfilippo syndrome, an inherited neurodegenerative lysosomal storage disorder, progressive loss of learned skills, sleep disturbance and behavioural problems occur. A potential therapy method is the repeated injection of the enzyme into cerebrospinal fluid via cisterna magna leading to a reduction of the number of lysosomal storage inclusions in the brain with a significant decrease in the immunohistochemical staining of a lysosomal membrane marker, and to reduced numbers of activated isolectin-B4-positive microglia and GFAP-positive astrocytes in some brain regions, phenotype, mouse model, overview
Display the word mapDisplay the reaction diagram Show all sequences 3.10.1.1more repeated human enzyme injection into murine cerebrospinal fluid via cisterna magna leads to a reduction of heparan sulfate-derived monosulfated disaccharide in the brain and spinal cord, reduced lysosomal vesicle formation in various cell types, reduced axonal spheroids, and improved behaviour of treated mice, mouse model, overview
Results 1 - 8 of 8